Paediatric orbital lymphoma; a case series and review of the literature

Keren, Shay; Lapira, Matthew; McCallum, Ewan; Sipkova, Zuzana; Qureshi, Amrana; Wilson, Shaun; Norris, Jonathan H.; Hildebrand, Göran Darius

doi:10.1038/s41433-022-02266-1

Cited by 5 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taking into consideration the findings of this study, the previous literature, and the poor treatment effects of only surgery for lymphoma, the treatment methods in this study were categorized into 4 groups, i.e., only surgery group, radiotherapy or surgery + radiotherapy group, chemotherapy or surgery + chemotherapy group, and chemoradiotherapy or surgery + chemoradiotherapy group. DISCUSSION B-cell lymphoma is the dominant primary orbital lymphoma type, accounting for more than 90% of all primary orbital lymphomas [1][2][3][6][7] . In the present study, there were 70 patients with B-cell lymphoma, accounting for 97.2% of all tumors.…”

Section: Pathological Subtypesmentioning

confidence: 99%

Predicting the prognosis of primary orbital lymphoma by clinical characteristics and imaging features

Zhu¹,

Zhang²,

Wang³

2023

Int J Ophthalmol

View full text Add to dashboard Cite

AIM: To analyze the 5-year disease-free survival (DFS) of primary orbital lymphoma (POL) by clinical characteristics and imaging features. METHODS: A total of 72 patients, 43 males and 29 females, with histologically confirmed POL, were retrospectively recruited between January 2012 and May 2017. The information on clinical characteristics, imaging features, and 5-year DFS was obtained. Univariate and multivariate forward logistic regression analyses were used to identify the variables significantly associated with 5-year DFS. Kaplan-Meier was applied for survival analysis. RESULTS: Univariate analysis revealed that uni- or bilateral orbital involvement, single or multiple lesions, treatment methods, and contrast enhancement pattern on images were significant for 5-year DFS (P=0.022, 0.042, <0.001, and 0.028, respectively), while in multivariate logistic regression analysis, only uni- or bilateral orbital involvement, treatment methods and contrast enhancement pattern on images were significant (r=0.453, 0.897, and 0.556, P=0.038, <0.001 and 0.022, respectively). The survival curves for DFS were obtained. CONCLUSION: The majority of POL are B-cell lymphomas. Unilateral orbital involvement, homogeneous contrast enhancement on images, and the appropriate treatment schemes result to be significant factors for a good prognosis for POL.

show abstract

Section: Pathological Subtypesmentioning

confidence: 99%

Predicting the prognosis of primary orbital lymphoma by clinical characteristics and imaging features

Zhu¹,

Zhang²,

Wang³

2023

Int J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Though usually benign and locally infiltrative, rarer malignant forms can develop and metastasize [17]. Orbital tumours in the paediatric age group are uncommon, and Keren et al describe a series of paediatric orbital lymphomas [18].…”

mentioning

confidence: 99%

Ocular oncology demystified

Chadha

Sagoo

2022

Eye

View full text Add to dashboard Cite

Ocular oncology occupies a unique position in ophthalmology. Not only are these conditions sight threatening, but they are also capable of eye loss, and many have the potential to shorten life. This issue, borne out of the symposium "Ocular Oncology Demystified" at The Royal College of Ophthalmologists, is dedicated to our late colleagues, Victoria Cohen, FRCOphth and John Hungerford, FRCS, FRCOphth.

show abstract

Hematological Second Primary Malignancy in Pediatric Retinoblastoma: A Case Report and Systematic Review

Hyun Park,

Young Park,

Kim

et al. 2024

Ophthalmic Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Purpose: The impact of heredity and treatment modalities on the development of hematologic second primary malignancies (SPMs) is unclear. This study primarily reviewed the literature on patients with hematologic SPMs after retinoblastoma. Methods: The PubMed and Web of Science databases were searched to identify all cases of hematologic SPMs after retinoblastoma through December 2023 (International prospective register of systematic reviews CRD42023488273). Results: Sixty-one patients from 35 independent publications and our case were included. Within the cohort, 15 patients (51.7%) were male, and 14 patients (48.3%) were female. Of the 43 cases with known heritability status, 27 (62.8%) were classified as heritable and 16 (37.2%) as nonheritable. The median age at diagnosis was 18 months (IQR: 7.00–36.00). The geographic distribution of patients was diverse, with North America accounting for 35.0% (21/60) of cases. The following treatment strategies were used: 11.9% (5/42) of patients received neither chemotherapy nor radiotherapy, 33.3% (14/42) received chemotherapy alone, 11.9% (5/42) received radiotherapy alone, and 42.9% (18/42) received a combination of chemotherapy and radiotherapy. The median delay between retinoblastoma diagnosis and SPM diagnosis was 40 months (IQR: 22.00–85.00). Among the 61 cases, acute myeloid leukemia accounted for 44.3% (27/61), followed by acute lymphoblastic leukemia in 21.3% (13/61), Hodgkin’s lymphoma in 11.5% (7/61), non-Hodgkin’s lymphoma in 9.8% (6/61), chronic myeloid leukemia in 3.3% (2/61), and acute natural killer cell leukemia in 1.6% (1/61). Conclusions: Vigilant systemic surveillance for hematologic SPMs in retinoblastoma survivors, especially those treated with systemic chemotherapy and those with hereditary conditions, is warranted to improve management strategies and patient outcomes.

show abstract

Paediatric orbital lymphoma; a case series and review of the literature

Cited by 5 publications

References 25 publications

Predicting the prognosis of primary orbital lymphoma by clinical characteristics and imaging features

Predicting the prognosis of primary orbital lymphoma by clinical characteristics and imaging features

Ocular oncology demystified

Hematological Second Primary Malignancy in Pediatric Retinoblastoma: A Case Report and Systematic Review

Contact Info

Product

Resources

About